Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab or ...

Combining reduced-dose olaparib with radium-223 improved rPFS in mCRPC patients, especially those without prior docetaxel and limited bone metastases. The combination's efficacy is based on mechanisms ...

Enzalutamide plus ADT significantly improves 5-year overall survival in mHSPC, with a 30% reduction in death risk compared to placebo plus ADT. The survival benefit of enzalutamide is consistent ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Dr Shore discussed the potential for ultra-low PSA response to serve as an end point in future clinical trials. He highlighted how this metric could potentially influence precision medicine approaches ...

Prostate-specific membrane antigen (PSMA) expression in renal cell carcinoma (RCC) was an incidental finding but shows potential. Uncertainty regarding frequency of PSMA expression across RCC subtypes ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

Welcome back to Pearls & Perspectives! In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Diane K. Newman, DNP, a nationally recognized expert in pelvic health, to explore ...

Future Directions for Imaging in Kidney Cancer Main Discussion Topics: Potential for deep learning and artificial intelligence (AI) to extract additional information from imaging data sets Recognition ...

Dr Murray on pembrolizumab counseling: “I split treatments into those we continue to put inside your bladder that patients are familiar with, and then pembrolizumab, which is FDA approved but ...

ARANOTE’s overall survival data are still maturing. ARASENS data show a promising trend for survival benefit. Competing risks and care access issues complicate survival analysis. Treatment completion ...